OneMedNet Corporation (NASDAQ: ONMD) has filed a Rule 424(b)(3) prospectus supplement with the U.S. Securities and Exchange Commission, updating its existing registration statement by incorporating its quarterly financial results for the period ended March 31, 2026. The filing registers a primary offering of up to 11.5 million common shares while also allowing the resale of up to 28.15 million shares by existing stockholders. The supplement does not represent a new fundraising announcement but rather updates previously registered securities with the company’s latest financial information.
Quarterly Results Reveal Ongoing Financial Challenges
The attached first-quarter Form 10-Q shows that OneMedNet reported a net loss of approximately $2.45 million for the three months ended March 31, 2026. The company ended the quarter with cash and cash equivalents of roughly $233,000, while using approximately $1.54 million in operating cash during the period. Management acknowledged that its current cash resources are insufficient to fund operations for the next 12 months without securing additional financing, resulting in a continued going concern disclosure.
Financing Flexibility Remains in Place
The filing also highlights OneMedNet’s existing Standby Equity Purchase Agreement (SEPA) with Yorkville, which provides the company with the ability to sell up to $25 million of common stock, subject to specified conditions and limitations. This financing arrangement offers management additional flexibility to raise capital if market conditions permit, although future share issuances could increase shareholder dilution.
Nasdaq Compliance and Investor Considerations
In addition to liquidity concerns, the filing notes that OneMedNet has received a Nasdaq minimum bid price notice after its share price fell below the exchange’s $1.00 requirement. The company has until October 12, 2026, to regain compliance or face potential delisting procedures, subject to Nasdaq’s rules. Investors are also reminded that the large number of registered shares available for resale could increase selling pressure if existing shareholders decide to dispose of their holdings.
Looking Ahead
The prospectus supplement primarily serves as a regulatory update rather than introducing a new capital raise. However, it underscores the company’s reliance on additional financing to support operations while continuing to expand its AI-ready healthcare data platform. Going forward, investors are likely to monitor OneMedNet’s capital-raising efforts, liquidity position, Nasdaq compliance progress, and operational performance as key indicators of its financial stability and growth prospects.
